This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Investigation of Vascular Inflammation in Migraine Using Molecular Nano-imaging and Black Blood Imaging MRI

This study is currently recruiting participants.
See Contacts and Locations
Verified January 2017 by Sabrina Khan, Danish Headache Center
Sponsor:
Information provided by (Responsible Party):
Sabrina Khan, Danish Headache Center
ClinicalTrials.gov Identifier:
NCT02549898
First received: July 31, 2015
Last updated: January 16, 2017
Last verified: January 2017
  Purpose
The investigators aim to investigate inflammation of cranial and meningeal arteries during pharmacologically induced migraine attacks, using ultrasmall superparamagnetic iron oxide (USPIO) nanoparticles and black blood imaging (BBI) MRI.

Condition Intervention
Migraine Headache Migraine Without Aura Drug: Feraheme Drug: Cilostazol Other: USPIO-MRI Other: BBI-MRI

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Official Title: Investigation of Vascular Inflammation in Migraine Without Aura Using Molecular Nano-imaging and Black Blood Imaging MRI

Resource links provided by NLM:


Further study details as provided by Sabrina Khan, Danish Headache Center:

Primary Outcome Measures:
  • USPIO uptake during attacks of unilateral migraine without aura [ Time Frame: 2 days ]
    On the first study day, intravenous infusion of Feraheme (USPIO) is delivered, and on the second study day, USPIO-MRI is performed.


Secondary Outcome Measures:
  • Arterial wall edema during attacks of unilateral migraine without aura [ Time Frame: 1 day ]
    On the first study day, arterial wall thickness prior to and during migraine is detected using BBI-MRI.


Estimated Enrollment: 42
Study Start Date: August 2015
Estimated Study Completion Date: June 2017
Estimated Primary Completion Date: June 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Vascular inflammation
Subjects with habitual unilateral migraine without aura, undergo pharmacological induction of a migraine attack, and subsequently are MRI scanned prior to and after Feraheme (USPIO) infusion.
Drug: Feraheme
Feraheme is an USPIO agent, which will be applied as a contrast agent to visualize vascular inflammation in unilateral migraine without aura.
Other Name: Ferumoxytol
Drug: Cilostazol
Cilostazol will be applied to provoke migraine attacks in migraineurs
Other Name: Pletal
Other: USPIO-MRI
USPIO-MRI scans will be performed in order to assess possible vascular inflammation associated with migraine attacks.
Other: BBI-MRI
Black blood MRI scans will be performed in order to asses changes in vessel wall thickness due to possible vascular inflammation associated with migraine attacks.
Experimental: Effect of sumatriptan
Subjects with habitual unilateral migraine without aura, undergo pharmacological induction of a migraine attack. Sumatriptan is given and subjects subsequently undergo MRI scans prior to and after Feraheme (USPIO) infusion.
Drug: Feraheme
Feraheme is an USPIO agent, which will be applied as a contrast agent to visualize vascular inflammation in unilateral migraine without aura.
Other Name: Ferumoxytol
Drug: Cilostazol
Cilostazol will be applied to provoke migraine attacks in migraineurs
Other Name: Pletal
Other: USPIO-MRI
USPIO-MRI scans will be performed in order to assess possible vascular inflammation associated with migraine attacks.
Other: BBI-MRI
Black blood MRI scans will be performed in order to asses changes in vessel wall thickness due to possible vascular inflammation associated with migraine attacks.
Experimental: Pilot
Subjects with habitual unilateral migraine without aura are MRI scanned prior to and after infusion of Feraheme (USPIO) on a migraine-free day.
Drug: Feraheme
Feraheme is an USPIO agent, which will be applied as a contrast agent to visualize vascular inflammation in unilateral migraine without aura.
Other Name: Ferumoxytol
Other: USPIO-MRI
USPIO-MRI scans will be performed in order to assess possible vascular inflammation associated with migraine attacks.
Other: BBI-MRI
Black blood MRI scans will be performed in order to asses changes in vessel wall thickness due to possible vascular inflammation associated with migraine attacks.

Detailed Description:

Migraine is the most common neurological disorder, ranked as the 7th most debilitating disease worldwide by the WHO. While much research has been and continues to be conducted to illuminate the enigma of migraine pathophysiology, key aspects still remain a conundrum. Specifically, the process of headache generation is perhaps the most complex and debated part of migraine pathophysiology. The vascular hypothesis of migraine has traditionally focused on the simple dilatation of cranial arteries. However, a possible contribution of perivascular pain sensitive structures should also be considered, as aseptic inflammation of the arterial walls and perivascular space may activate afferent nerve endings. Interestingly, giant cell arteritis caused by aseptic arterial wall inflammation may present clinically as localized headache with migraine-like features (i.e. throbbing pain, localized in the temporal region, and allodynia).

The primary trigeminal nociceptor is the first integral part of the headache-generating pathway. Animal models of migraine have suggested that activation and sensitization of perivascular trigeminal nociceptors caused by inflammatory substances may explain head pain in migraine. However, there is no human evidence to date to suggest perivascular and arterial wall inflammation as a source of pain in migraine.

The investigators hypothesize that unilateral migraine without aura is associated with ipsilateral inflammation of the cranial arteries and meninges. The investigators also suggest that sumatriptan inhibits this perivascular inflammation. To test the hypotheses the investigators will perform MRI scans on subjects with provoked migraine attacks, using two different methods to visualize perivascular inflammation: USPIO-MRI, using iron-oxide nanoparticles as contrast agent, and BBI MRI.

To pharmacologically induce migraine headache in the study subjects, the investigators will use the drug cilostazol, which is a phosphodiesterase 3 inhibitor.

  Eligibility

Ages Eligible for Study:   18 Years to 40 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Written informed consent
  • Subject has migraine without aura according to criteria of the International Headache Society (IHS)
  • Subject has unilateral migraine 70% of the time
  • Migraine can be pharmacologically provoked in the subject using cilostazol.
  • Subject is on birth control
  • Subject has no other medical history

Exclusion Criteria:

  • Subject suffers from bilateral migraine
  • Subject suffers from migraine with aura
  • Subject suffers from other primary headaches as specified by IHS criteria
  • Pregnant or breast feeding subjects
  • Subjects with contraindications for undergoing MRI scans
  • Any known drug allergy
  • Any signs or disorders of iron overload, including but not limited to hemosiderosis and porphyria cutanea tarda
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02549898

Contacts
Contact: Sabrina Khan, MD 004538633066 sabrina.khan@regionh.dk

Locations
Denmark
Danish Headache Center & Department of Neurology Recruiting
Glostrup Copenhagen, Denmark, 2600
Contact: Sabrina Khan, MD    30310516 ext +45    sabrina.khan@regionh.dk   
Sponsors and Collaborators
Danish Headache Center
Investigators
Principal Investigator: Sabrina Khan, MD Danish Headache Center
  More Information

Responsible Party: Sabrina Khan, Medical Doctor and PhD student, Danish Headache Center
ClinicalTrials.gov Identifier: NCT02549898     History of Changes
Other Study ID Numbers: H-15005669
Study First Received: July 31, 2015
Last Updated: January 16, 2017

Additional relevant MeSH terms:
Inflammation
Migraine Disorders
Headache
Migraine without Aura
Pathologic Processes
Headache Disorders, Primary
Headache Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Pain
Neurologic Manifestations
Signs and Symptoms
Cilostazol
Sumatriptan
Ferrosoferric Oxide
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Fibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action
Platelet Aggregation Inhibitors
Vasodilator Agents
Neuroprotective Agents
Protective Agents
Phosphodiesterase 3 Inhibitors

ClinicalTrials.gov processed this record on September 19, 2017